Overview
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT06351592
Status
Recruiting
Start/End Dates
Locations
Djavad Mowafaghian Centre for Brain Health
Vancouver General Hospital
Name/Title
Nimmy George, Research Coordinator
Phone
Email Address
Purpose of Study
The purpose of this Phase 1b/2 study is to evaluate an experimental drug, ALN-SOD, in a small group of participants for the first time. Phase I trials assess safety, determine appropriate dosage ranges and identify potential side effects. This study focuses on individuals with amyotrophic lateral sclerosis (ALS) who have a change in the SOD1 gene. The primary aim of the study is to see how safe and tolerable the study treatment (ALN-SOD) is in humans.
Eligible participants will be given doses of ALN-SOD or placebo into the fluid surrounding the spinal cord (intrathecal injection). The study doctor will do this by inserting a needle into the spine (spinal tap/lumbar puncture). During study visits, participants will also answer questions about their health and will undergo lumbar punctures. Participation may last up to four and a half years with up to 27 study visits, including some overnight stays for dosing.
Eligibility
Visit clinicaltrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
The purpose of this Phase 1b/2 study is to evaluate an experimental drug, ALN-SOD, in a small group of participants for the first time. Phase I trials assess safety, determine appropriate dosage ranges and identify potential side effects. This study focuses on individuals with amyotrophic lateral sclerosis (ALS) who have a change in the SOD1 gene. The primary aim of the study is to see how safe and tolerable the study treatment (ALN-SOD) is in humans.
Eligible participants will be given doses of ALN-SOD or placebo into the fluid surrounding the spinal cord (intrathecal injection). The study doctor will do this by inserting a needle into the spine (spinal tap/lumbar puncture). During study visits, participants will also answer questions about their health and will undergo lumbar punctures. Participation may last up to four and a half years with up to 27 study visits, including some overnight stays for dosing.
Visit clinicaltrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.